CBDNext Supra Capsule

CBDNext Supra Capsule contains 40 mg purified CBD isolate (99.8% purity, pharmaceutical-grade) adsorbed onto a proprietary solid matrix using Micro Matrix Technology™.

COMPOSITION: CBD isolate adsorbed onto a solid matrix with polyoxyethylene sorbitan fatty acid esters (polysorbate 80), maltodextrin, stearic acid, and a silica derivative. Delivered in a hard gelatin capsule.

REFERENCE PRODUCT (comparator in the study): Standard CBD isolate capsule containing 40 mg CBD isolate with microcrystalline cellulose (MCC) only — no bioavailability-enhancing excipients.

KEY DISTINCTION: The CBDNext Supra composition uses a high-HLB nonionic emulsifier (surfactant), organic acid, and polysaccharide carrier to create a self-emulsifying system that forms fine micelles upon contact with GI fluids — without requiring dietary fat for absorption.

MANUFACTURING: Produced by Imuneks Farma (Turkey) under cGMP conditions. Patent-protected composition covering the specific excipient ratios and processing method.

THE BIOAVAILABILITY PROBLEM WITH CBD: CBD is highly lipophilic (log P ~6.3) with extremely poor water solubility (~0.001 mg/mL). Standard oral CBD undergoes extensive first-pass metabolism with only 6–19% reaching systemic circulation. Absorption is highly variable and dependent on dietary fat content — creating unpredictable consumer experiences.

HOW MICRO MATRIX SOLVES THIS: The solid-state self-emulsifying matrix in CBDNext Supra creates its own emulsification environment upon contact with GI fluids. Unlike oil-based CBD products that rely on dietary fat for micelle formation, the Micro Matrix composition contains built-in emulsifiers (polysorbate 80) and carriers (maltodextrin) that spontaneously form fine micelles regardless of fed/fasted state.

MECHANISM OF ENHANCED ABSORPTION: Step 1 — Capsule dissolves in stomach, releasing the solid matrix. Step 2 — Matrix contacts GI fluids and self-emulsifies, forming fine micelles (typically <100 nm). Step 3 — CBD is presented to the intestinal epithelium in a pre-solubilised, bioavailable form. Step 4 — Enhanced lymphatic uptake bypasses some first-pass hepatic metabolism. Step 5 — Result: higher, faster, more consistent systemic CBD levels.

WHY THIS MATTERS COMMERCIALLY: The dramatic reduction in variability (CV% from >134% to ~27%) means every consumer gets a consistent experience. This solves the #1 complaint with CBD products: 'it works for my friend but not for me.' The inconsistency is usually a bioavailability problem, not a CBD problem.

Key takeaway: Micro Matrix Technology transforms CBD from a highly variable, fat-dependent compound into a predictable, self-emulsifying delivery system. The published human data proves this works — it's not theoretical.

PUBLICATION: 'Randomized single-dose crossover comparative bioavailability study of two novel oral cannabidiol (CBD) formulations in healthy volunteers under fed conditions, compared to a standard CBD isolate capsule.' Journal of Cannabis Research (2025), Volume 7, Article 54. DOI: 10.1186/s42238-025-00312-9.

AUTHORS: Pisak MN, Bereket E, Erenmemisoglu A.

STUDY DESIGN: Randomized, single-dose, three-period crossover study. Each subject received all three formulations (CBDNext Supra Capsule, CBDNext Supra Liquid, and Reference CBD Isolate) with 7-day washout periods between each dose. This crossover design means each subject serves as their own control — the gold standard for bioavailability comparison.

SUBJECTS: 9 healthy adult volunteers (18–55 years). Fed conditions: standardised low-fat breakfast (approximately 400 kcal, <25% fat) consumed 30 minutes before dosing. This is important because it tests a realistic consumer scenario, not an optimised high-fat meal.

DOSE: 40 mg CBD per formulation (identical dose across all three arms). Blood sampling: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72 hours post-dose. Analytical method: Validated LC-MS/MS for CBD and 7-OH-CBD metabolite.

REGULATORY COMPLIANCE: Study conducted in accordance with ICH-GCP guidelines. Ethics committee approved. All subjects provided written informed consent. Registered clinical trial.

PRIMARY ENDPOINT — Cmax (Peak Plasma Concentration): CBDNext Supra Capsule: 14.1 ng/mL. CBDNext Supra Liquid: 6.20 ng/mL. Reference CBD Isolate: 2.44 ng/mL. FOLD IMPROVEMENT: Capsule is 5.7× higher than reference (geometric mean ratio 566%, 90% CI: 356–900%).

PRIMARY ENDPOINT — AUC₀₋₇₂ (Total Systemic Exposure): CBDNext Supra Capsule: 38.0 h·ng/mL. CBDNext Supra Liquid: 20.2 h·ng/mL. Reference CBD Isolate: 11.7 h·ng/mL. FOLD IMPROVEMENT: Capsule is 3.3× higher than reference (geometric mean ratio 328%, 90% CI: 226–478%).

SECONDARY ENDPOINT — Tmax (Time to Peak): CBDNext Supra Capsule: median 2.0 hours. CBDNext Supra Liquid: median 1.0 hours. Reference CBD Isolate: median 6.0 hours. INTERPRETATION: 3× faster onset for capsule; 6× faster for liquid. Consumers feel effects sooner.

CRITICAL FINDING — Variability (CV%): CBDNext Supra Capsule: ~27% CV. CBDNext Supra Liquid: ~44% CV. Reference CBD Isolate: >134% CV. INTERPRETATION: The reference product is so variable that some subjects get almost nothing while others get high levels. CBDNext Supra delivers consistent levels across all subjects.

METABOLITE CONFIRMATION — 7-Hydroxy-CBD: Capsule Cmax 1.8 ng/mL vs Reference 0.4 ng/mL. This confirms genuine systemic absorption and hepatic metabolism — the CBD is truly reaching the bloodstream, not just dissolving in the GI tract.

SAFETY: No serious adverse events. Only treatment-related AE: mild-to-moderate transient headache in 4 subjects. No clinically significant changes in liver function tests. Plasma cortisol remained within normal ranges throughout.

DOSE EQUIVALENCE: The 5.7× Cmax improvement means that a 40 mg CBDNext Supra dose achieves plasma levels that would require approximately 228 mg of standard CBD isolate. This has direct implications for dosing efficiency and cost-effectiveness for consumers.

VARIABILITY AS THE KEY DIFFERENTIATOR: The CV% reduction from >134% to ~27% is arguably the most commercially significant finding. High variability in standard CBD products means unpredictable consumer experiences — some feel nothing, others feel too much. CBDNext Supra delivers consistent results across individuals regardless of their metabolic profile or recent food intake.

COMPETITIVE POSITIONING: This is a peer-reviewed, published human pharmacokinetic study on the actual finished product. Most competing CBD bioavailability claims rely on: (a) in vitro dissolution data only, (b) preclinical animal data, (c) unpublished internal studies, or (d) claims about the delivery technology without product-specific human data. CBDNext Supra has the highest evidence tier available.

MARKET OPPORTUNITY: The global CBD market suffers from a credibility problem — too many products with unsubstantiated claims. A published, peer-reviewed human study provides the scientific foundation that serious retailers, healthcare practitioners, and regulatory bodies require.

Important: This study was conducted under fed (low-fat) conditions. Results may differ under fasted conditions or with high-fat meals. The study used a 40 mg dose; extrapolation to other doses should be made cautiously. Bioavailability improvement does NOT automatically equal therapeutic efficacy — that would require separate efficacy studies.

APPROVED CLAIMS (safe to use): 'Peer-reviewed human study demonstrates 5.7× higher peak CBD levels' | 'Published in Journal of Cannabis Research (2025)' | 'Clinically shown to reduce dosing variability (CV% 27% vs >134%)' | 'Micro Matrix Technology for enhanced CBD delivery' | 'Faster onset — median 2 hours vs 6 hours for standard CBD' | '3.3× greater total CBD exposure vs standard isolate capsule' | 'Self-emulsifying solid-state delivery system'

PROHIBITED CLAIMS (never use): 'Treats anxiety, pain, inflammation, or any disease' | 'FDA approved' | 'Medical-grade CBD' | 'Guaranteed therapeutic effect' | 'Replaces prescription CBD (Epidiolex)' | 'Cures insomnia' | '100× bioavailability' (actual is 5.7× Cmax, 3.3× AUC) | 'Works better than all other CBD products' | 'Doctor recommended'

CRITICAL DISTINCTION: You may cite the bioavailability data freely because it comes from a published peer-reviewed study. However, bioavailability improvement does NOT equal therapeutic efficacy. Higher blood levels of CBD do not automatically mean better health outcomes — that would require separate efficacy studies. You are selling BETTER DELIVERY, not BETTER THERAPY.

SOCIAL MEDIA GUIDANCE: Always link to the published study when making bioavailability claims. Use exact numbers from the publication (5.7×, 3.3×, 27% CV). Never extrapolate to therapeutic claims. The study is your strongest asset — use it precisely and let the data speak.

Key takeaway: CBDNext Supra has the strongest evidence tier of any MN Nutra product (published human PK study in a peer-reviewed journal). Use this as the flagship evidence story. But always distinguish between 'higher absorption' (proven) and 'treats disease' (not proven and not claimable).

Required FDA Disclaimer: 'These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.'